Core Viewpoint - Xidian Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 18.89% but a recent decline in the last five trading days by 4.10% [1] Company Overview - Xidian Pharmaceutical, established on March 21, 1990, and listed on February 23, 2022, is located in Jilin Province and specializes in the research, production, and sales of chemical pharmaceutical raw materials and formulations [1] - The company's main revenue sources are: Risperidone orally disintegrating tablets (54.15%) and Compound Ferrous Sulfate Folic Acid Tablets (45.13%), with other products contributing 0.72% [1] Financial Performance - For the period from January to September 2025, Xidian Pharmaceutical reported operating revenue of 189 million yuan, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 33.14 million yuan, down 2.70% year-on-year [1] - As of September 30, the number of shareholders decreased by 2.91% to 7,863, while the average circulating shares per person increased by 2.97% to 7,426 shares [1] Market Activity - On November 25, Xidian Pharmaceutical's stock rose by 2.05% to 30.90 yuan per share, with a trading volume of 5.4471 million yuan and a turnover rate of 0.30%, resulting in a total market capitalization of 2.364 billion yuan [1] - The stock has experienced a decline of 1.65% over the past 20 days and 5.65% over the past 60 days [1] Dividend Information - Since its A-share listing, Xidian Pharmaceutical has distributed a total of 63.34 million yuan in dividends, with 52.83 million yuan distributed over the past three years [2]

Core Viewpoint - Huadong Medicine's stock price has shown a mixed performance in recent trading sessions, with a year-to-date increase of 22.30% but a decline of 2.39% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77% [2] - The net profit attributable to shareholders for the same period was 2.748 billion yuan, reflecting a year-on-year increase of 7.24% [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders decreased by 1.50% to 68,800, while the average number of circulating shares per person increased by 1.53% to 25,466 shares [2] - The company has cumulatively distributed 8.873 billion yuan in dividends since its A-share listing, with 3.771 billion yuan distributed over the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the third-largest circulating shareholder, holding 52.004 million shares, an increase of 12.1653 million shares from the previous period [3] - China Securities Finance Corporation remains the fourth-largest shareholder with 22.1868 million shares, unchanged from the previous period [3] - Notable changes in holdings include a decrease of 4.3243 million shares for the fifth-largest shareholder, China Universal Healthcare Mixed A [3]

11月24日，中恒集团盘中上涨2.28%，截至09:52，报2.69元/股，成交3694.26万元，换手率0.43%，总市 值85.95亿元。 分红方面，中恒集团A股上市后累计派现29.41亿元。近三年，累计派现6874.28万元。 机构持仓方面，截止2025年9月30日，中恒集团十大流通股东中，南方中证1000ETF（512100）位居第 五大流通股东，持股2423.75万股，相比上期减少64.15万股。香港中央结算有限公司位居第六大流通股 东，持股2408.94万股，相比上期减少142.43万股。汇添富中证中药ETF（560080）位居第七大流通股 东，持股1655.74万股，为新进股东。华夏中证1000ETF（159845）位居第八大流通股东，持股1440.69 万股，为新进股东。广发中证1000ETF（560010）位居第十大流通股东，持股1114.05万股，为新进股 东。 责任编辑：小浪快报 资料显示，广西梧州中恒集团股份有限公司位于广西梧州工业园区工业大道1号，成立日期1993年7月28 日，上市日期2000年11月30日，公司主营业务涉及对医药、能源、基础设施、城市公用事业、酒店旅游 业、物流业 ...

贵州百灵今年以来股价涨47.27%，近5个交易日跌8.25%，近20日跌2.74%，近60日跌9.86%。 分红方面，贵州百灵A股上市后累计派现14.47亿元。近三年，累计派现0.00元。 11月21日，贵州百灵（维权）盘中下跌2.07%，截至10:09，报5.67元/股，成交4205.22万元，换手率 0.61%，总市值79.24亿元。 资金流向方面，主力资金净流出500.95万元，特大单买入0.00元，占比0.00%，卖出367.11万元，占比 8.73%；大单买入746.30万元，占比17.75%，卖出880.14万元，占比20.93%。 资料显示，贵州百灵企业集团制药股份有限公司位于贵州省安顺市经济技术开发区西航路212号，成立 日期1999年3月25日，上市日期2010年6月3日，公司主营业务涉及以苗药为主的中成药的生产、销售。 主营业务收入构成为：中成药86.97%，西药8.44%，医疗服务2.27%，其他1.91%，中药材0.42%。 贵州百灵所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：抗流感、低价、民营医院、 中药、肝炎治疗等。 截至11月10日，贵州百灵股东户数8.58万，较 ...

11月21日，开开实业盘中下跌2.06%，截至10:09，报14.28元/股，成交1.53亿元，换手率6.56%，总市值 37.51亿元。 资金流向方面，主力资金净流出1055.20万元，特大单买入0.00元，占比0.00%，卖出648.79万元，占比 4.24%；大单买入2197.28万元，占比14.36%，卖出2603.69万元，占比17.01%。 开开实业所属申万行业为：医药生物-医药商业-医药流通。所属概念板块包括：SPD概念、民营医院、 小盘、中药、医药电商等。 截至9月30日，开开实业股东户数3.37万，较上期减少7.03%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，开开实业实现营业收入8.25亿元，同比增长10.76%；归母净利润1286.78万元，同比减少 62.81%。 分红方面，开开实业A股上市后累计派现1.91亿元。近三年，累计派现3474.90万元。 机构持仓方面，截止2025年9月30日，开开实业十大流通股东中，招商证券(香港)有限公司位居第三大 流通股东，持股113.11万股，持股数量较上期不变。BOCI SECURITIES LIMITED位居第七大流通股 东 ...

Core Viewpoint - Huadong Medicine's stock price has experienced fluctuations, with a year-to-date increase of 19.81% but a recent decline of 6.51% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77%, and a net profit attributable to shareholders of 2.748 billion yuan, up 7.24% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders decreased by 1.50% to 68,800, while the average circulating shares per person increased by 1.53% to 25,466 shares [2] - The company has distributed a total of 8.873 billion yuan in dividends since its A-share listing, with 3.771 billion yuan distributed over the past three years [3] Stockholder Composition - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 12.1653 million shares to 52.0036 million shares [3] - China Securities Finance Corporation maintained its position as the fourth-largest shareholder with 22.1868 million shares, while other notable shareholders saw reductions in their holdings [3] Business Overview - Huadong Medicine, established on March 31, 1993, and listed on January 27, 2000, is primarily engaged in the production and sale of various pharmaceutical products, with a revenue composition of 64.45% from commercial activities and 39.69% from manufacturing [1] - The company operates in several sectors, including vitamins, traditional Chinese medicine, hepatitis treatment, pharmaceutical e-commerce, and medical aesthetics [1]

Core Viewpoint - Yunnan Yixintang Pharmaceutical Group Co., Ltd. has experienced a decline in stock price and financial performance in 2025, with a notable drop in revenue and net profit compared to the previous year [1][2]. Financial Performance - As of September 30, 2025, Yixintang reported a revenue of 13 billion yuan, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million yuan, down 8.17% from the previous year [2]. - The company has cumulatively distributed dividends of 2.023 billion yuan since its A-share listing, with 764 million yuan distributed over the last three years [3]. Stock Market Activity - On November 21, Yixintang's stock price fell by 2.03% to 13.04 yuan per share, with a trading volume of 42.388 million yuan and a turnover rate of 0.81%, resulting in a total market capitalization of 7.636 billion yuan [1]. - The stock has increased by 4.07% year-to-date but has seen declines of 7.97% over the last five trading days, 5.98% over the last 20 days, and 13.38% over the last 60 days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 10.53% to 37,500, with an average of 10,596 circulating shares per shareholder, a decrease of 9.53% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, increasing its holdings by 3.74 million shares [3].

Core Viewpoint - The stock of Furuida has experienced a decline, with a current price of 7.75 yuan per share and a market capitalization of 7.878 billion yuan, reflecting a challenging financial performance in recent periods [1][2]. Company Performance - Furuida's stock price has increased by 3.33% year-to-date, but it has seen a decline of 3.00% over the last five trading days, 1.77% over the last 20 days, and 9.57% over the last 60 days [1]. - For the period from January to September 2025, Furuida reported a revenue of 2.597 billion yuan, a year-on-year decrease of 7.34%, and a net profit attributable to shareholders of 142 million yuan, down 17.19% year-on-year [2]. Shareholder and Market Activity - As of September 30, 2025, Furuida had 44,500 shareholders, a decrease of 6.27% from the previous period, with an average of 22,827 circulating shares per shareholder, an increase of 6.69% [2]. - The company has made cumulative cash distributions of 1.196 billion yuan since its A-share listing, with 213 million yuan distributed over the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 4.6498 million shares, having decreased its holdings by 70,900 shares compared to the previous period [3].

截至9月30日，开开实业股东户数3.37万，较上期减少7.03%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，开开实业实现营业收入8.25亿元，同比增长10.76%；归母净利润1286.78万元，同比减少 62.81%。 责任编辑：小浪快报 分红方面，开开实业A股上市后累计派现1.91亿元。近三年，累计派现3474.90万元。 开开实业今年以来股价跌9.66%，近5个交易日跌2.49%，近20日涨1.63%，近60日跌1.22%。 今年以来开开实业已经1次登上龙虎榜，最近一次登上龙虎榜为1月2日，当日龙虎榜净买入-1120.05万 元；买入总计5518.17万元 ，占总成交额比8.51%；卖出总计6638.22万元 ，占总成交额比10.24%。 资料显示，上海开开实业股份有限公司位于上海市静安区昌平路678号一楼，成立日期1997年8月4日， 上市日期2001年2月28日，公司主营业务涉及以中医药流通、中医药学服务(中医问诊服务)和服装批 发、零售为主营业务。主营业务收入构成为：批发类74.48%，零售类18.18%，卫生服务类4.42%，租赁 类1.77%，其他1.14%。 机构持仓方面， ...

Core Viewpoint - Kangyuan Pharmaceutical's stock has experienced a decline of 2.06% on November 19, with a current price of 15.20 CNY per share and a market capitalization of 8.606 billion CNY [1] Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion CNY, representing a year-on-year decrease of 24.66% [1] - The net profit attributable to the parent company for the same period was 200 million CNY, down 44.10% year-on-year [1] Stock Market Activity - The stock has increased by 11.60% year-to-date, but has seen a decline of 2.56% over the last five trading days, 1.75% over the last twenty days, and 23.35% over the last sixty days [1] - As of November 19, the net outflow of main funds was 6.4392 million CNY, with large orders accounting for 13.10% of purchases and 20.70% of sales [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 17.20% to 40,500, while the average circulating shares per person decreased by 14.68% to 13,969 shares [1] - The total cash dividends distributed by Kangyuan Pharmaceutical since its A-share listing amount to 949.8 million CNY, with 345 million CNY distributed over the past three years [2] Company Overview - Kangyuan Pharmaceutical, established on May 8, 1996, and listed on September 18, 2002, is located in Lianyungang, Jiangsu Province, and specializes in the research, production, and sales of pharmaceuticals [1] - The company's main business revenue composition includes 58.68% from oral medications, 33.28% from injections, and 8.04% from external applications [1] - The company is classified under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [1]